Form 4: Seres Therapeutics Director Granted Stock Options
Statement of Changes in Beneficial Ownership
Seres Therapeutics Director Dennis A. Ausiello was granted stock options for 7,508 shares of common stock.
Summary
- Director Dennis A. Ausiello of Seres Therapeutics, Inc. was granted stock options on July 1, 2026.
- The options are for 7,508 shares of common stock with an exercise price of $7.94 per share.
- These options vest in four equal quarterly installments, starting October 1, 2026, and concluding on July 1, 2027, contingent on continued service as a non-employee director.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard compensation event for a director rather than financial performance or strategic changes.
Positives
- Grant of stock options to a director indicates potential alignment of management and shareholder interests.
- The vesting schedule encourages continued service and commitment to the company's performance.
Risks
- The value of the stock options is subject to the future performance of Seres Therapeutics' stock price.
- Vesting is contingent on continued service, meaning the director could forfeit unvested options if they leave the board.
Future Outlook
The filing itself does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports a transaction related to director compensation.
Industry Context
StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term shareholder value creation, especially for companies in development stages.
Related Party Transactions
- The grant of stock options to Director Dennis A. Ausiello is a related party transaction.
Stakeholder Impact
- Shareholders: The grant of options aligns director incentives with stock performance, potentially benefiting shareholders if the stock price increases.
- Employees: Indirect impact through potential improved company performance driven by aligned leadership.
- Creditors: No direct impact from this compensation-related filing.
Next Steps
- Director Dennis A. Ausiello will continue to serve on the Board of Directors.
- Stock options will vest quarterly through July 1, 2027, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 07/01/2026 | Earliest transaction date and grant date of stock options. |
| 10/01/2026 | First quarterly vesting installment for stock options. |
| 01/01/2027 | Second quarterly vesting installment for stock options. |
| 04/01/2027 | Third quarterly vesting installment for stock options. |
| 07/01/2027 | Final quarterly vesting installment for stock options, or the day prior to the 2027 annual meeting if it occurs before this date. |
Keywords
Seres Therapeutics, MCRB, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.